PLoS ONE (Jul 2009)

Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo.

  • Beatrice Cousin,
  • Emmanuel Ravet,
  • Sandrine Poglio,
  • Fabienne De Toni,
  • Mélanie Bertuzzi,
  • Hubert Lulka,
  • Ismahane Touil,
  • Mireille André,
  • Jean-Louis Grolleau,
  • Jean-Marie Péron,
  • Jean-Pierre Chavoin,
  • Philippe Bourin,
  • Luc Pénicaud,
  • Louis Casteilla,
  • Louis Buscail,
  • Pierre Cordelier

DOI
https://doi.org/10.1371/journal.pone.0006278
Journal volume & issue
Vol. 4, no. 7
p. e6278

Abstract

Read online

BackgroundNormal tissue homeostasis is maintained by dynamic interactions between epithelial cells and their microenvironment. Disrupting this homeostasis can induce aberrant cell proliferation, adhesion, function and migration that might promote malignant behavior. Indeed, aberrant stromal-epithelial interactions contribute to pancreatic ductal adenocarcinoma (PDAC) spread and metastasis, and this raises the possibility that novel stroma-targeted therapies represent additional approaches for combating this malignant disease. The aim of the present study was to determine the effect of human stromal cells derived from adipose tissue (ADSC) on pancreatic tumor cell proliferation.Principal findingsCo-culturing pancreatic tumor cells with ADSC and ADSC-conditioned medium sampled from different donors inhibited cancer cell viability and proliferation. ADSC-mediated inhibitory effect was further extended to other epithelial cancer-derived cell lines (liver, colon, prostate). ADSC conditioned medium induced cancer cell necrosis following G1-phase arrest, without evidence of apoptosis. In vivo, a single intra-tumoral injection of ADSC in a model of pancreatic adenocarcinoma induced a strong and long-lasting inhibition of tumor growth.ConclusionThese data indicate that ADSC strongly inhibit PDAC proliferation, both in vitro and in vivo and induce tumor cell death by altering cell cycle progression. Therefore, ADSC may constitute a potential cell-based therapeutic alternative for the treatment of PDAC for which no effective cure is available.